Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma

被引:91
作者
Antinori, A
Perno, CF
Giancola, ML
Forbici, F
Ippolito, G
Hoetelmans, RM
Piscitelli, SC
机构
[1] IRCCS, Natl Inst Infect Dis, Clin Dept, I-00149 Rome, Italy
[2] Tibotec Virco, Mechelen, Belgium
[3] Tibotec Virco, Raritan, NJ USA
关键词
D O I
10.1086/498310
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Cerebrospinal fluid (CSF) concentrations of multiple drugs in a large human immunodeficiency virus (HIV)-infected patient population, the virtual phenotype profiles for HIV in the plasma and CSF compartments, and the correlation of these profiles with exposure to antiretroviral therapy need to be further investigated. Methods. Drug concentrations in CSF and plasma were concomitantly determined for a large group of HIV-infected individuals receiving highly active antiretroviral therapy (HAART). Samples were analyzed using a validated method consisting of liquid chromatography with mass spectrometry. For patients with detectable levels of virus, genotypic analysis was performed, followed by a virtual phenotype study. Results. Sixty-three HIV-infected patients were included in the study, 78% of whom were affected by neurological disease. Drug concentrations in CSF specimens were undetectable for didanosine, efavirenz, nelfinavir, and concomitantly administered ritonavir and saquinavir. CSF concentrations were higher for nevirapine, with a median CSF-to-plasma concentration ratio of 0.63, followed by lamivudine (0.23), stavudine (0.20), and indinavir (0.11). In 18 of the 40 patients with virtual phenotype data available for virus recovered from CSF samples and from plasma samples, differences in fold-change of resistance between the CSF virus and the plasma virus were noted for at least 1 drug. Factors associated with having differences in fold-change of resistance were number of drugs to which the patient had been exposed (P = .02) and presence of neurological disease (P = .05). A significant association was found between duration of therapy and fold-change of resistance in CSF and plasma isolates. Conclusions. Antiretrovirals have different levels of penetration in the CSF, with several drugs achieving only low CSF concentrations. CSF isolates have different resistance profiles than do plasma isolates. Effective treatment decisions for CSF manifestations of disease may require better knowledge of drug penetration and the drug susceptibility of HIV in the CSF.
引用
收藏
页码:1787 / 1793
页数:7
相关论文
共 36 条
[1]   Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro [J].
Albright, AV ;
Erickson-Viitanen, S ;
O'Connor, M ;
Frank, I ;
Rayner, MM ;
González-Scarano, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (15) :1527-1537
[2]   Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients [J].
Antinori, A ;
Giancola, ML ;
Grisetti, S ;
Soldani, F ;
Alba, L ;
Liuzzi, G ;
Amendola, A ;
Capobianchi, M ;
Tozzi, V ;
Perno, CF .
AIDS, 2002, 16 (14) :1867-1876
[3]  
Arendt G., 2002, Current Drug Targets - Infectious Disorders, V2, P187, DOI 10.2174/1568005023342425
[4]   Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex [J].
Aweeka, F ;
Jayewardene, A ;
Staprans, S ;
Bellibas, SE ;
Kearney, B ;
Lizak, P ;
Novakovic-Agopian, T ;
Price, RW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :39-43
[5]   Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy [J].
Baxter, JD ;
Merigan, TC ;
Wentworth, DN ;
Neaton, JD ;
Hoover, ML ;
Hoetelmans, RMW ;
Piscitelli, SC ;
Verbiest, WHA ;
Mayers, DL .
AIDS, 2002, 16 (08) :1131-1138
[6]   GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy [J].
Bossi, P ;
Peytavin, G ;
Ait-Mohand, H ;
Delaugerre, C ;
Ktorza, N ;
Paris, L ;
Bonmarchand, M ;
Cacace, R ;
David, DJ ;
Simon, A ;
Lamotte, C ;
Marcelin, AG ;
Calvez, V ;
Bricaire, F ;
Costagliola, D ;
Katlama, C .
HIV MEDICINE, 2004, 5 (05) :352-359
[7]   Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals [J].
Burger, D ;
Hugen, P ;
Reiss, P ;
Gyssens, I ;
Schneider, M ;
Kroon, F ;
Schreij, G ;
Brinkman, K ;
Richter, C ;
Prins, J ;
Aarnoutse, R ;
Lange, J .
AIDS, 2003, 17 (08) :1157-1165
[8]  
CINGOLANI A, 2003, 10 C RETR OPP INF BO
[9]   PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results [J].
Clevenbergh, P ;
Garraffo, R ;
Durant, J ;
Dellamonica, P .
AIDS, 2002, 16 (17) :2311-2315
[10]   A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy [J].
Cohen, CJ ;
Hunt, S ;
Sension, M ;
Farthing, C ;
Conant, M ;
Jacobson, S ;
Nadler, J ;
Verbiest, W ;
Hertogs, K ;
Ames, M ;
Rinehart, AR ;
Graham, NM .
AIDS, 2002, 16 (04) :579-588